Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology

For combination therapy, we treated the guinea pigs i.p. The first trial assessed a chimeric monoclonal antibody CGP 47,439 to the V3 loop of the HIV-1 envelope gp120 over 21 weeks [66,67]. In the study, Thorpe and his colleagues tested the compound on guinea pigs in an advanced stage of infection with a form of the Lassa fever virus, a disease that affects parts of West Africa. It’s quick, easy, and affordable. Therefore, all patients with first episodes of genital herpes should receive antiviral therapy. By targeting an aspect of infected cells in the host, he thinks bavituximab is less likely to lose effectiveness, which commonly happens when a virus mutates. Peregrine Pharmaceuticals, Inc.

(, which provides development and biomanufacturing services for both Peregrine and outside customers. About the Phase II HCV Trial In this multicenter Phase II randomized, open-label trial, up to 66 patients with previously untreated genotype-1 chronic HCV infection will be randomly assigned to one of three treatment arms. Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. & dev. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. A growing body of scientific publications, including Nature Medicine and The Journal of Experimental Medicine, has highlighted data on the role of PS and Peregrine’s PS-targeting therapies in infectious diseases. DALLAS — Nov 23, 2008 — Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Dr. In the second study, guinea pigs were infected with lethal Pichinde virus, which is a model virus for Lassa fever. Thorpe and his colleagues at UT Southwestern is exclusively licensed to Peregrine. No dose-limiting toxicities occurred and a maximum tolerated dose of bavituximab was not reached. This review discusses the current immune-based strategies currently approved, as well as various immune approaches being actively investigated including monoclonal antibodies, checkpoint inhibitors, vaccines, and adoptive T-cell therapies. CD25, also known as interleukin-2 receptor subunit-α; GITR, glucocorticoid-induced TNFR-related protein; ICOS, inducible T cell co-stimulator; LAG3, lymphocyte activation gene 3 protein; PD1, programmed cell death protein 1; TNFRSF25, tumour necrosis factor receptor superfamily member 25; VEGFR, vascular endothelial growth factor receptor.

The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab while seeking a partner to further advance its novel brain cancer agent Cotara®. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that enrollment of the Phase III trial may experience delays or take longer than anticipated, the risk that the results from the Phase III trial may not support a future Biologics License Application (BLA) submission, the risk that the company may not have or raise adequate financial resources to complete the Phase III trial and the risk that the company may not find a suitable partner for the Phase III trial or the PS program. Under a major biodefense initiative, bavituximab and a fully human equivalent antibody are in preclinical development for the treatment of viral hemorrhagic fevers under a federal contract worth up to $44.4 million. Peregrine Pharmaceuticals, Inc. PS, a lipid molecule normally found only on the inside of cell membranes, becomes exposed on the outside of the membranes of viruses and virally infected cells. backbone listen (BAK-bone) The bones, muscles, tendons, and other tissues that reach from the base of the skull to the tailbone. I also take coconut oil, cooking with it is great!!

The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. In previous preclinical studies funded by NIAID, bavituximab demonstrated encouraging anti-viral activity as a potential treatment for hemorrhagic fevers. With bavituximab’s immune reactivation mechanisms and safety profile to date, we are eager to assess this new combination as a potential alternative to interferon-based regimens for patients infected with HCV.”Bavituximab may address a fundamental “immune evasion” mechanism exploited by many infectious pathogens. Bavituximab as a monotherapy also showed promising on therapy antiviral activity of up to 1.5 log viral load reduction. Selective binding to bavituximab-coated plates was observed (Fig. Ocular Herpes (Acute HSV-1 Keratitis), see • PGN650 is a human F(ab’)2 fragment that targets PS expression (1st ref’d in AACR’12 #2452) – see . Aggressive treatment with antiviral medication is required, but it may not help systemic herpes.

However, the possibility remains that bavituximab inhibits viral replication in macrophages or another cell reservoir for Pichinde virus in vivo.

Leave a Reply